{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T22:37:55Z","timestamp":1792103875086,"version":"4.4.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,11]],"date-time":"2021-02-11T00:00:00Z","timestamp":1613001600000},"content-version":"vor","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016193","name":"University of Colorado School of Medicine, Anschutz Medical Campus","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016193","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.jacc.2019.11.050","type":"journal-article","created":{"date-parts":[[2020,2,3]],"date-time":"2020-02-03T18:59:23Z","timestamp":1580756363000},"page":"498-508","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["Long-Term Outcomes and Associations With Major Adverse Limb Events After Peripheral Artery Revascularization"],"prefix":"10.1016","volume":"75","author":[{"given":"Connie N.","family":"Hess","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Weleski Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Gundrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy M.","family":"Allen LaPointe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Kevin","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William R.","family":"Hiatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2019.11.050_bib1","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis","volume":"382","author":"Fowkes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2019.11.050_bib2","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jvs.2009.01.035","article-title":"National trends in lower extremity bypass surgery, endovascular interventions, and major amputations","volume":"50","author":"Goodney","year":"2009","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jacc.2019.11.050_bib3","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.jvs.2008.11.054","article-title":"Patterns of treatment for peripheral arterial disease in the United States: 1996\u20132005","volume":"49","author":"Rowe","year":"2009","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jacc.2019.11.050_bib4","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.jvs.2016.03.429","article-title":"Contemporary cardiovascular risk and secondary preventive drug treatment patterns in peripheral artery disease patients undergoing revascularization","volume":"64","author":"Sigvant","year":"2016","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jacc.2019.11.050_bib5","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.amjcard.2015.11.025","article-title":"In-hospital outcomes of atherectomy during endovascular lower extremity revascularization","volume":"117","author":"Panaich","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2019.11.050_bib6","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/j.jvs.2017.01.061","article-title":"Regional variation in outcomes for lower extremity vascular disease in the Vascular Quality Initiative","volume":"66","author":"Soden","year":"2017","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jacc.2019.11.050_bib7","doi-asserted-by":"crossref","first-page":"93","DOI":"10.7326\/M17-1058","article-title":"Readmissions after revascularization procedures for peripheral arterial disease: a nationwide cohort study","volume":"168","author":"Secemsky","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2019.11.050_bib8","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1161\/CIRCULATIONAHA.117.027625","article-title":"Thirty-day readmissions after endovascular or surgical therapy for critical limb ischemia: analysis of the 2013 to 2014 Nationwide Readmissions Databases","volume":"136","author":"Kolte","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.050_bib9","article-title":"Hospital readmissions following endovascular therapy for critical limb ischemia: associations with wound healing, major adverse limb events, and mortality","volume":"5","author":"Reed","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.jacc.2019.11.050_bib10","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/j.jacc.2008.07.060","article-title":"Progression of peripheral arterial disease predicts cardiovascular disease morbidity and mortality","volume":"52","author":"Criqui","year":"2008","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.11.050_bib11","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1016\/j.jacc.2017.02.040","article-title":"Burden of readmissions among patients with critical limb ischemia","volume":"69","author":"Agarwal","year":"2017","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.11.050_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ahj.2016.06.002","article-title":"Significant variation in P2Y12 inhibitor use after peripheral vascular intervention in Medicare beneficiaries","volume":"179","author":"Jones","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2019.11.050_bib13","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jvs.2014.03.290","article-title":"Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population","volume":"60","author":"Nehler","year":"2014","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jacc.2019.11.050_bib14","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jvs.2014.03.244","article-title":"Trends in the incidence, treatment, and outcomes of acute lower extremity ischemia in the United States Medicare population","volume":"60","author":"Baril","year":"2014","journal-title":"J\u00a0Vasc Surg"},{"key":"10.1016\/j.jacc.2019.11.050_bib15","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jacc.2018.06.041","article-title":"Major adverse limb events and 1-year outcomes after peripheral artery revascularization","volume":"72","author":"Hess","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.11.050_bib16","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1001\/jama.2010.1322","article-title":"Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis","volume":"304","author":"Bhatt","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2019.11.050_bib17","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2174\/157016110791112304","article-title":"The importance of early diagnosis and treatment in peripheral arterial disease: insights from the PARTNERS and REACH registries","volume":"8","author":"Mukherjee","year":"2010","journal-title":"Curr Vasc Pharmacol"},{"key":"10.1016\/j.jacc.2019.11.050_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1161\/CIRCULATIONAHA.110.003954","article-title":"Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004","volume":"124","author":"Pande","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.050_bib19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1611688","article-title":"Ticagrelor versus clopidogrel in symptomatic peripheral artery disease","volume":"376","author":"Hiatt","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacc.2019.11.050_bib20","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1161\/CIRCULATIONAHA.112.000679","article-title":"Vorapaxar in patients with peripheral artery disease: results from TRA2\u00b0P-TIMI 50","volume":"127","author":"Bonaca","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.050_bib21","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1161\/CIRCULATIONAHA.117.024469","article-title":"A\u00a0structured review of antithrombotic therapy in peripheral artery disease with a focus on revascularization: a TASC (InterSociety Consensus for the Management of Peripheral Artery Disease) initiative","volume":"135","author":"Hess","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.050_bib22","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.116.025880","article-title":"Ticagrelor compared with clopidogrel in patients with prior lower extremity revascularization for peripheral artery disease","volume":"135","author":"Jones","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.050_bib23","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.jacc.2018.07.046","article-title":"Cardiovascular outcomes after lower extremity endovascular or surgical revascularization: the EUCLID trial","volume":"72","author":"Baumgartner","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.11.050_bib24","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1161\/CIRCULATIONAHA.115.019355","volume":"133","author":"Bonaca","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2019.11.050_bib25","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.jacc.2018.03.008","article-title":"Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS Trial","volume":"71","author":"Anand","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2019.11.050_bib26","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.atherosclerosis.2013.10.027","article-title":"Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: differences between peripheral and coronary angioplasty","volume":"232","author":"Gremmel","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacc.2019.11.050_bib27","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1016\/j.jacc.2016.03.524","article-title":"Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease","volume":"67","author":"Bonaca","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719386838?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109719386838?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T16:05:28Z","timestamp":1751645128000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109719386838"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0735109719386838"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2019.11.050","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-Term Outcomes and Associations With Major Adverse Limb Events After Peripheral Artery Revascularization","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2019.11.050","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}]}}